All cases of clinically identified hepatitis that occurred during military service were routinely and obligatorily admitted to civilian hospitals and were routinely tested for hepatitis B surface antigen.4 Men serve a compulsory period of three years and women two years. A proportion of subjects served longer than the compulsory period and a relatively smaller 117 group.bmj.com on July 7, 2017 -Published by
Hepatitis A is endemic in Israel.1 2 By the age of 18, 60 to 700/%, of the population have antibodies to hepatitis A virus (HAV).3 Over 900/ of cases of viral hepatitis in the Israel Defence Forces are non-B. Within the framework of a controlled trial of pre-exposure immune serum globulin (ISG) for prevention of non B hepatitis in over 23 000 male and female army recruits initiated in 1977,4 a study of the serological incidence of hepatitis A was undertaken in a sample of the men and women. The objective of this report is to compare the incidence of serological HAV infection in the immunised and non-immunised groups, and to estimate the ratio of clinical to serological infection in the study population.
Methods
The characteristics of the study population that participated in a controlled trial of pre-exposure ISG prophylaxis in the Israel Defence Forces and the study design are described in a prior report. 4 Briefly, in 1977, 23 447 recruits were allocated by service number to an intervention group and a control group of equal size. The intervention group received a 5 ml intramuscular injection of ISG (Cutter Laboratories, USA) on the day of induction into service. HAV antibody was measured in an overlapping sample drawn the same year. Antibody to hepatitis A virus (anti-HAV) was found on intake in 80-85% of recruits of Eastern origin (father or grandfather born in North Africa or the Middle East) and in 30-40% of those of Western origin (Europe and the Americas).3 Logistic reasons and expense prevented routine laboratory examination of anti-HAV on the day of induction in all recruits. Thus ISG was administered without regard to anti-HAV status.
All cases of clinically identified hepatitis that occurred during military service were routinely and obligatorily admitted to civilian hospitals and were routinely tested for hepatitis B surface antigen.4 Men serve a compulsory period of three years and women two years. A proportion of subjects served longer than the compulsory period and a relatively smaller 117 Jeremy D Kark, Shulamith Bar-Shany, Smadar Shor, Leah Merlinski, and Eliezer Nili proportion served a shorter period. The cumulative incidence of clinical non B hepatitis was calculated for three years follow up in 12 835 male participants in the trial." This slightly underestimates the actual rates due to inflation of the denominator because subjects released early were regarded as having served a full period.
On intake, a sample of trial participants randomised according to service number had blood drawn. The sera were stored at -20 C. On the day of release from service an effort was made to reascertain this sample and draw a second blood specimen. Men were ascertained on release from three to four years' service and women after two to three years' service. Subjects released from duty before completing their compulsory service period or those who served more than an additional year were not sought. Examination of the sample who had blood drawn on recruitment showed that service duration was equally distributed between the trial groups.
There was a higher proportion of immunised than non-immunised participants among those contacted on discharge from service (53% v 47% Table 1 shows the distribution of subjects in the serological study who received ISG and those who did not. At recruitment 1014 sera were taken from men and 674 from women. These were nearly equally distributed between immunised and non-immunised. On discharge from service we contacted 701 men (690%o) and 207 women (31%Y,). Of these, 41 men and Table 1 Number of sera taken at recruitment and at discharge and number and proportion of paired sera that were anti HA V negative at recruitment separately by sex and immunisation group for all subjects and for those who served no more than their normal compulsory service period There was a total of 214 men and 89 women with paired sera who had been HAV antibody negative at recruitment, and of those who completed no more than their compulsory service 154 men and 73 women had been negative. As seen in Table 1 , the proportion of initially seronegative men in those with paired sera was similar in the two trial groups, whereas in women with paired sera there was a higher proportion of seronegatives among the immunised group (p = 0.042).
These subjects who had been HAV antibody negative were the only ones who might have benefited from immunisation, and they are now analysed in further detail to ascertain conversion rates. Table 2 shows the number of subjects who converted from HAV antibody negative during their service. Of the total 303 subjects negative at recruitment who had paired sera, 17 (5.6%/,) had seroconverted at discharge. But within the immunised and non-immunised groups only 6 out of 119 174 (3.4%) immunised subjects converted whereas 11 out of 129 (8.5%) non-immunised converted (p = 0-050). The sex adjusted odds ratio was 2 5 with 95% confidence limits ranging from 0-8 to 8-0. In the 227 initially seronegative subjects discharged after no more than normal service the seroconversion rate was 8-9% in the immunised group and 2-4% in the non-immunised (p = 0.029). The sex adjusted odds ratio was 4-0 (95% confidence limits 1-3 to 19-0).
For both men and women the non-immunised groups experienced two to fourfold more seroconversion than the immunised groups. For men discharged after normal service the difference was of borderline statistical significance (p = 0.052), while for both sexes together the 95% confidence limits of the adjusted odds ratio excluded unity. Differences between the trial groups were somewhat smaller and less significant for the total follow up.
Possible confounding factors considered were ethnic origin3 and army classification score.9 The classification score determines placement and roles of personnel in service and hence may be considered an indicator of exposure to infection, while ethnicity reflects attributes that may be associated with both exposure and susceptibility. The distribution of these variables in the two trial groups and the overall seroconversion proportions in the two main origin groups (Europe and Asia-North Africa) were sufficiently similar to rule out confounding by these factors as an explanation for the findings.
An ethnic stratified analysis showed, however, that the association was confined to the European origin group in both sexes and was statistically significant (p Table 2 Status at discharge ofpersons negative to anti HA V at recruitment by sex and immunisation group showing the conversion rates and odds ratio for all subjects and those with no more than normal service duration Of the 17 subjects who converted at the time of discharge five had had clinically diagnosed HBsAg negative hepatitis during their service, four men and one woman. The proportion of converters who had overt hepatitis was 0-29 (exact binomial 95%/ confidence limits 0-10 to 0.56).
A second approach was also used to estimate the ratio of clinically manifest infections to serological infections. Table 3 shows clinical morbidity data from the cohort of 12 835 male trial participants followed up for three years. Women were not analysed by this method. The three year cumulative incidence of HBsAg negative hepatitis among 6417 men not immunised was 46 (7.2 per 1000) and among 6418 men allocated to immunisation was 23 (3.6 per 1000).5 The statistical significance of this difference using Fisher's exact test was p = 0-004. On the assumption that 350/% of the total male population was seronegative at recruitment and that all clinical cases of non B hepatitis occurred in these negative subjects then the three year cumulative incidence becomes 20-5 per 1000 in the non-immunised and 10-2 per 1000 in the immunised. The ratio of the clinical infection rate in the susceptibles to the three year seroconversion rate was 0-26 (950%6 confidence limits 0. 13 to 0.52). When the seroconversion rate from the total follow up sample was used the ratio became 0-24. The data were too small to give separate estimates of the ratio of clinical cases to seroconversion for the intervention and control groups.
Discussion
The difference in the incidence rates of seroconversion among the immunised and non-immunised groups suggests that the HAV antibody content of the ISG in the dose administered on intake, which unfortunately we did not measure in this study, suppressed seroconversion, possibly by neutralisation of infective doses of virus as proposed by Mosley.10 It is noteworthy that this difference was identifiable in men three years after receipt of ISG in the trial although the effect in terms of risk ratios would be expected to be 'diluted' by infection occurring in both trial groups after protection subsided. The detailed clinical morbidity data reported elsewhere5 suggest that ISG may provide some protection for more than 6-9 months. The only initial difference between the two trial groups (those allocated to receive ISG and those not) lay in their immunisation status at induction. Many were subsequently immunised annually during their service, some up to three times. The allocation procedure in this trial and the large sample size should assure that subsequent immunisations with ISG during the follow up period, exposure to virus during service, and susceptibility to disease were equally distributed in the two trial groups. In our sample of seronegative subjects, the findings could not be attributed to confounding by ethnicity or by the army classification score. Therefore, the difference in seroconversion rates probably reflects either the effect of the initial ISG immunisation or a chance finding which could occur three to five times in a hundred with the sample size examined here. However, the possibility of an unidentified bias resulting from loss to follow up and unequal ascertainment of serological samples in the two trial groups cannot be excluded. The In a study of HAV infections in households in Costa Rica, a hyperendemic area for hepatitis A,20 most infections in adults over the age of 20 were inapparent. Of considerable interest was the observation that an immunoglobulin M response was absent in a progressively larger proportion of 121 inapparent infections, ranging from 20% in the 5-9 year age group to 97% in those aged 20+. The authors suggest that this finding indicates restimulation of immunoglobulin G antibodies by reinfection. Had a similar phenomenon occurred in the current study, i.e. that a portion of the seroconversions were indeed reinfections, then the seroconversion rate and hence the ratio of seroconversion to clinical disease in previously uninfected people could be overestimated.
ISG appears to suppress seroconversion, an effect that may be viewed as negative because HAV infected subjects do not develop protective antibody and thus remain susceptible to subsequent infection when the protective ISG effect wears off. However, this effect of ISG administration at intake in our population is of little public health significance because about 90% of the initially susceptible, non-immunised participants versus more than 95% of the immunised recruits remained seronegative over three years' follow up-a trivial difference from the viewpoint of population susceptibility to future infection. ISG given on the day of recruitment into military service was a highly effective preventive measure and was preferable to the policy of post-exposure prophylaxis that prevailed before this trial.
